市场调查报告书
商品编码
1499509
二十碳五烯酸的全球市场:按来源、形式和应用分类 - 预测(2024-2030)Eicosapentaenoic Acid Market by Source (Algae, Fish, Krill), Form (Ethyl Esters, Triglycerides), Application - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年全球二十碳五烯酸市场规模将达8.625亿美元,2024年将达到9.0494亿美元,复合年增长率为5.16%,2030年将达到12.2744亿美元。
二十碳五烯酸 (EPA) 是一种长链Omega-3脂肪酸,主要存在于油性鱼类、鱼油补充品和某些藻类中。 EPA 市场涵盖其生产、精製以及在各行业的应用。 EPA 的市场包括药品、食品、食品和饮料、动物营养品等,强调其多样化的应用和对最终消费者的好处。生质燃料和生质塑胶等新应用的技术创新正在扩大 EPA 市场的范围,增加成长和发展的潜力。消费者健康意识的提高以及对天然营养食品的渴望是 EPA 需求的主要驱动力。正在进行的研究证明 EPA 在治疗和管理各种健康状况方面的有效性,支持其在医学上的应用。鼓励在食品和膳食食品中使用Omega-3的有利法规将对市场成长产生积极影响。对永续EPA 来源(包括微藻类)的日益关注,为具有环保意识的市场适应提供了重要机会。此外,宠物医疗保健支出的增加预计也将扩大二十碳五烯酸在动物营养领域的应用范围。
主要市场统计 | |
---|---|
基准年[2023] | 8.625 亿美元 |
预测年份 [2024] | 90494万美元 |
预测年份 [2030] | 12.2744亿美元 |
复合年增长率(%) | 5.16% |
区域洞察
由于消费者对 omega-3 营养素的认知度较高且医疗保健产业成熟,美洲成为 EPA 的重要市场。由于重视预防医学以及人口老化,人们更容易患心血管疾病,该地区对营养食品中所含的EPA的需求强劲。美国在製药领域占有重要地位,EPA 广泛用于治疗高三酸甘油脂血症的製剂中。包括 FDA 在内的对Omega-3疗法的监管支持进一步巩固了该地区的市场成长。主要市场参与者的存在,加上积极的营销策略和有关Omega-3脂肪酸益处的消费者教育,正在推动市场扩张。在健康意识和可支配收入不断提高的推动下,亚太地区二十碳五烯酸市场正在快速成长,特别是在中国、日本和印度等国家。日本是EPA最大的消费国之一,由于其传统的多吃鱼的饮食习惯,拥有很大的市场占有率。在该地区,随着消费者越来越关注预防医学,对营养食品的需求正在迅速增加。此外,在亚太国家,旨在开发心血管和神经退化性疾病先进治疗方法的製药业的扩张进一步推动了对 EPA 的需求。产品开发的创新,加上水产养殖的发展,特别是重点养殖富含 EPA 的鱼类,预计将提升该地区的市场成长潜力。在 EMEA(欧洲、中东和非洲)地区,人们对二十碳五烯酸的兴趣正在增加,尤其是在欧洲。人们越来越认识到Omega-3脂肪酸的效用,加上越来越多的老年人口更容易患慢性病,正在推动对富含 EPA 的营养食品的需求。欧洲国家对膳食食品有严格的规定,是基于 EPA 的高品质药品的一个前景看好的市场。由于健康意识的增强和医疗基础设施的改善,中东和非洲是具有巨大成长潜力的新兴市场。虽然欧洲是一个注重创新和严格品质标准的成熟市场,但由于经济多元化和对预防性医疗保健日益增长的兴趣,中东和非洲正在提供开拓的机会。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在二十碳五烯酸市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对二十碳五烯酸市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对二十碳五烯酸市场目前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[186 Pages Report] The Eicosapentaenoic Acid Market size was estimated at USD 862.50 million in 2023 and expected to reach USD 904.94 million in 2024, at a CAGR 5.16% to reach USD 1,227.44 million by 2030.
Eicosapentaenoic acid (EPA) is a long-chain omega-3 fatty acid primarily found in oily fish, fish oil supplements, and certain algae. The market for EPA encompasses its production, purification, and applications across various industries. The terrain of the EPA market includes pharmaceuticals, dietary supplements, food & beverages, and animal nutrition, highlighting its diversification in usage and end-consumer benefits. The scope of the EPA market is expanding, with innovation driving into new applications, including biofuels and bioplastics, indicating a broad horizon for growth and development. Growing consumer awareness regarding health and wellness, alongside the desire for natural dietary supplements, significantly drives the demand for EPA. Continuous research substantiating EPA's efficacy in treating and managing various health conditions bolsters its adoption in pharmaceuticals. Favorable regulations encouraging the use of omega-3s in food and dietary supplements positively affect market growth. Growing attention to sustainable sources of EPA, including microalgae, presents a significant opportunity for eco-conscious market adaptation. Additionally, rising pet healthcare expenditures are also expected to boost the scope for eicosapentaenoic acid within animal nutrition segments.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 862.50 million |
Estimated Year [2024] | USD 904.94 million |
Forecast Year [2030] | USD 1,227.44 million |
CAGR (%) | 5.16% |
Regional Insights
The Americas represent a significant market for eicosapentaenoic acid (EPA) owing to the high awareness of omega-3 benefits among consumers and well-established healthcare sectors. The region shows a robust demand for EPA in dietary supplements due to the growing emphasis on preventive healthcare and an aging population prone to cardiovascular diseases. The U.S. holds a significant position in the pharmaceutical sector, where EPA is extensively utilized in formulations aimed at treating conditions including hypertriglyceridemia. The regulatory support from agencies including the FDA for omega-3-based therapeutic products further scaffolds the market growth in this region. The presence of major market players, coupled with aggressive marketing strategies and consumer education on the benefits of omega-3 fatty acids, bolsters the market expansion. The Asia-Pacific region is experiencing rapid growth in the eicosapentaenoic acid market, driven by rising health consciousness and disposable incomes, especially in countries including China, Japan, and India. Japan, being one of the largest consumers of EPA, holds a significant market share due to its traditional diet rich in fish. The region is witnessing a surge in the demand for dietary supplements as consumers are increasingly inclined towards preventive healthcare measures. Additionally, the expansion of the pharmaceutical sector in APAC countries, aimed at developing advanced treatment options for cardiovascular and neurodegenerative diseases, further propels the demand for EPA. Innovation in product development, coupled with an increase in the aquaculture industry, specifically focusing on EPA-rich fish farming, is set to boost the market's growth potential in this region. The EMEA region exhibits a growing interest in Eicosapentaenoic Acid, with Europe leading the charge. The increasing awareness about the benefits of omega-3 fatty acids, coupled with a rising elderly population susceptible to chronic diseases, fuels the demand for EPA-enriched dietary supplements. European countries, with their stringent regulatory frameworks for nutritional products, present a promising market for high-quality, EPA-based pharmaceuticals. The Middle East and Africa are emerging markets with vast growth potential, attributed to a gradual shift towards health and wellness trends and improving healthcare infrastructure. While Europe's mature market focuses on innovation and stringent quality standards, the Middle East and Africa offer untapped opportunities driven by economic diversification and an increasing focus on preventive healthcare.
Market Insights
The market dynamics represent an ever-changing landscape of the Eicosapentaenoic Acid Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Eicosapentaenoic Acid Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Eicosapentaenoic Acid Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
Amneal Pharmaceuticals, Inc. and Strides Pharma Science Limited announced their strategic collaboration for the introduction of Icosapent Ethyl soft gel capsules, a VASCEPA reference product. This innovative product, available in 0.5g and 1g dosages, is an adjunctive treatment to dietary adjustments to lower triglyceride levels in adults with severe hypertriglyceridemia (>=500 mg/dL). [Published On: 2023-12-01]
Biomar Forms Partnership to Commercialise Omega-3 Camelina
BioMar, a producer of salmon feed, entered into a strategic partnership with Yield10 Bioscience, a U.S.-based company, to bring to market a revolutionary genetically modified oilseed crop rich in omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), matching the levels found in traditional fish oil. This innovation presents a land-based, sustainable alternative for sourcing omega-3s, essential components in aquaculture feeds. [Published On: 2023-10-31]
Amarin and Neopharm Announce Exclusive Commercialization Agreement for Vazkepa (Icosapent Ethyl) in Israel
Amarin Corporation plc and Neopharm Israel officially announced their exclusive partnership for the marketing and commercializing of VAZKEPA (icosapent ethyl) in Israel, Gaza, the West Bank, and territories under the Palestinian Authority. VAZKEPA capsules, featuring icosapent ethyl as their sole active ingredient-a highly purified form of eicosapentaenoic acid-represent the first prescription therapy of its kind. This strategic alliance leverages Neopharm's significant expertise and strong presence in cardiology to ensure VAZKEPA's accessibility to patients in need, especially those at elevated cardiovascular risk. [Published On: 2023-08-08]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Eicosapentaenoic Acid Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Eicosapentaenoic Acid Market, highlighting leading vendors and their innovative profiles. These include AlgiSys BioSciences Inc., Archer Daniels Midland Company, Arctic Nutrition AG, Asterisk Laboratories (I) Pvt. Ltd., BASF SE, BIOSEARCH, SA, Cayman Chemical Company, Corbion N.V., Croda International PLC, Epax Norway AS, Evonik Industries AG, Golden Omega S.A., Indo Rama Engineers, KD Pharma Group, Koninklijke DSM N.V., Novasep Holding SAS, Novotech Nutraceuticals, Inc., Omega Protein Corporation, Orkla Health AS, Pelagia AS, Santa Cruz Biotechnology, Inc., Shandong Yuwang Pharmaceutical Co., Ltd., SimSon Pharma Limited, Sinomega Biotech Engineering Co.,Ltd., and Toronto Research Chemicals Inc..
Market Segmentation & Coverage